Compositions of stem cells and stem cell factors and methods for their use and manufacture

• US 8,790,638 B2
• Filed: 10/05/2009
• Issued: 07/29/2014
• Est. Priority Date: 02/04/2009
• Status: Active Grant

• Current Assignee: Stemedica Cell Technologies, Inc.
• Original Assignee: Stemedica Cell Technologies, Inc.
• Inventors: Tankovich, Nikolai, Kharazi, Alexander, Lin, Chih-Min
• Primary Examiner(s): Ford, Allison
• Application Number:
  US12/573,159
• Publication Number:
  US 20100209398A1
• Time in Patent Office: 1,758 Days
• Field of Search: None
• US Class Current: 424/93.7
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Therapeutic stem cells and methods for their use and manufacture. Stem cells are produced under conditions in which the stem cells are exposed to at least one environmental factor, including decreased oxygen tension. The environmental factors and culture conditions of the invention produce stem cells having an enhanced therapeutic ability and enhanced proliferation in culture. Stem cells of the invention retain their plasticity through a higher number of cell passages relative to know methods of stem cell culture.

Claims

1. A method for treating an ischemic stroke in a patient comprising:

a. intrathecally administering to the patient a therapeutic amount of neural stem cells; and

b. intravenously administering to the patient a therapeutically effective amount of mesenchymal stem cells;

wherein the neural stem cells have been exposed to reduced oxygen tension and the mesenchymal stem cells have been grown under reduced oxygen tension for a plurality of passages.

2. The method of claim 1, wherein the neural stem cells and the mesenchymal stem cells are cultured in a culture medium comprising serum.

3. The method of claim 1, wherein the mesenchymal stem cells are grown under reduced oxygen tension for four passages.